United States · Business Intelligence startup
United States · Yarrow
Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.
Funding reportedLast round: Venture - Series Unknown
What company datasets say Yarrow raised
Funding, as reported
Reported in all$200Min dollars
Last roundVenture - Series Unknown
Investors listed5
Founders and team
From Yarrow's own website: 2 on the team.
- Tyler ZerondaChief Financial Officer
- Steven L. HoerterBoard Member
On a portfolio page
Investors who name them
Each firm lists Yarrow on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Business Intelligence in United States
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Yarrow in front of investors. Or tell us what we have wrong.